Cagrilintide is an investigational long-acting amylin analog developed by Novo Nordisk, and as of this reference it carries no FDA or other major-regulator approval for any use. Its clinical program targets two linked metabolic problems, chronic weight management and type 2 diabetes, pursued most actively through the fixed-dose combination CagriSema, which pairs the amylin analog with semaglutide. Because the compound remains in trials, the people it is meant for are defined by study eligibility rather than a marketed label, generally adults who meet specific weight and health thresholds.
Cagrilintide is a trial-stage amylin analog aimed at chronic weight management and type 2 diabetes in adults meeting specific weight and health criteria, and it is not approved for prescription outside a clinical study.
The primary indication driving cagrilintide's development is chronic weight management in adults with obesity or overweight. As a long-acting analog of amylin, the pancreatic hormone that slows gastric emptying and promotes satiety, the compound is designed to extend that appetite-suppressing action into a once-weekly injection. Its most advanced path is not as a solo agent but as the amylin component of CagriSema, where it is combined with semaglutide to act on two satiety pathways at once.
Cagrilintide's primary indication is chronic weight management in adults with obesity or overweight, pursued most actively as the amylin component of the CagriSema combination with semaglutide.
Cagrilintide reaches type 2 diabetes care through CagriSema, the investigational fixed-dose combination that pairs the amylin analog with semaglutide, an established GLP-1 receptor agonist. The rationale is that amylin and GLP-1 act on distinct but complementary satiety and metabolic pathways, so the combination is intended to lower glucose and body weight more than either mechanism alone. The same product is studied in a diabetes arm and an obesity arm against different endpoints.
| Criterion | Obesity arm | Type 2 diabetes arm |
|---|---|---|
| Enrolled population | Adults with obesity or overweight, who may not have diabetes | Adults with type 2 diabetes and inadequate glycemic control |
| Primary endpoints | Percentage body weight reduction | Hemoglobin A1c reduction and body weight change |
| Mechanistic goal | Appetite suppression and weight loss | Combined glucose lowering and weight loss |
In the CagriSema program, cagrilintide is combined with semaglutide and studied in adults with type 2 diabetes and inadequate glycemic control against endpoints tracking both hemoglobin A1c reduction and body weight change.
Because cagrilintide is investigational, the people who are not candidates are defined by trial exclusion criteria rather than a marketed contraindication list, and those criteria are deliberately cautious. Several exclusions carry over from the GLP-1 component's known safety signals, and others reflect populations where the drug's effects are unestablished.
Cagrilintide trials exclude adults with type 1 diabetes, a personal or family history of medullary thyroid carcinoma or MEN 2, a history of pancreatitis, pregnant or breastfeeding individuals, and children, so eligibility is narrow and no one qualifies outside a supervised study.
The intended focus is not adults in general but a specific metabolic subset whose weight or blood sugar has crossed into a range where medical intervention is warranted. A recurring theme in this drug class is that the therapy is studied in people for whom diet and exercise have already proven insufficient, positioning the compound as an added tool rather than a first step.
The cagrilintide program targets a specific metabolic subset of adults, those with obesity or complicated overweight and those with type 2 diabetes for whom lifestyle measures alone have proven insufficient, not the general adult population.
Exploration beyond chronic weight management and type 2 diabetes is real but early and clearly secondary. Because sustained weight loss tends to ease a range of obesity-linked problems, scientific interest exists in several downstream conditions, but none of these rises to an established or approved use, and the primary evidence and regulatory attention stay fixed on obesity and diabetes.
Adjacent uses such as cardiovascular disease, obstructive sleep apnea, and metabolic dysfunction-associated fatty liver disease are explored only at the level of hypothesis and outcome tracking, and none is an established or approved cagrilintide indication.
As of this reference, cagrilintide is investigational and unapproved by the FDA, the European Medicines Agency, or other major regulators for any indication, whether on its own or within CagriSema. Investigational status means the compound is still under evaluation for safety and efficacy and cannot be marketed or prescribed as an ordinary medicine, so access runs through the narrow gate of trial participation rather than a prescription anyone can obtain.
Cagrilintide is investigational and unapproved by the FDA, the EMA, or other major regulators for any indication, so the only legitimate access is enrollment in a sponsored clinical trial under medical supervision.
Educational use only. This article describes what the published scientific and clinical literature reports about Cagrilintide. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
